Last reviewed · How we verify

NCT04176276

Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.

Completed Last updated 5 June 2020
What this trial tests

trial testing no interventions required. in Diabetic Kidney Disease in 300 participants. Completed in 1 March 2020.

Timeline
1 March 2018
Primary endpoint
31 December 2019
1 March 2020

Quick facts

Lead sponsorUniversity of Pisa
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date1 March 2018
Primary completion31 December 2019
Estimated completion1 March 2020
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Pisa

Who can join

Adults 18 to 75, any sex, with Diabetic Kidney Disease or Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetes kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in western countries and its incidence is worryingly increasing worldwide. Cardiovascular disease shows a continuous relationship with declining of renal function in type 2 diabetes patients. Moreover, there is a strong evidence of all-cause mortality risk excess even in patients with early stages kidney disease. MicroRNA (miRNA) are small non-coding RNA molecules, containing 21-25 nucleotides, that modulate post-transcriptional gene expressions. In the past years many human miRNAs involved in the pathogenesis of renal disease have been discovered, such as miR-192, miR-194, miR-204 and miR-25. Among these, miR-192 and miR-25, are receiving greater attention while it seems that they play a role in glomerulosclerosis and renal fibrosis. However too few data are available in large publish trials among patients with renal impairment and the role of serum and urinary levels of miR-192 and miR-25 in people with preserved renal function remain unclear. To evaluate the association between serum and urinary expression of miR-192 and miR-25 and renal function (according to different extent of renal impairment) in patients with or without type 2 diabetes.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Metabolic memory: mechanisms and diseases.
    Dong H, Sun Y, Nie L, Cui A, et al · · 2024 · cited 62× · PMID 38413567 · DOI 10.1038/s41392-024-01755-x
  2. Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery.
    Pandey A, Ajgaonkar S, Jadhav N, Saha P, et al · · 2022 · cited 14× · PMID 36297381 · DOI 10.3390/ph15101269
  3. Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.
    Zhou LY, Lin SN, Rieder F, Chen MH, et al · · 2021 · cited 11× · PMID 33324986 · DOI 10.1093/ibd/izaa321
  4. Let-7i-5p Regulation of Cell Morphology and Migration Through Distinct Signaling Pathways in Normal and Pathogenic Urethral Fibroblasts.
    Zhang K, Yang R, Chen J, Qi E, et al · · 2020 · cited 11× · PMID 32478052 · DOI 10.3389/fbioe.2020.00428

Verify or expand the search:

Other recruiting trials for Diabetic Kidney Disease

Currently open trials in the same condition.

Other University of Pisa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04176276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing